Queensland, Australia (CU)_ Astellas Venture Management LLC and LabCentral have announced that they will team up on the Future Innovator Prize, which is earlier known as the Astellas Golden Ticket Competition. Astellas is a wholly-owned venture capital subsidiary of Astellas Pharma Inc., and LabCentral is a supportive platform for early-stage life-sciences startups. The Future Innovator Prize provides entrepreneurial scientists or developing biotechnology start-up firms with one-year access to LabCentral’s modern innovative lab facility in Cambridge, Massachusetts, and Astellas’ research and development (R&D) resources and business executives.
Astellas’ sponsorship of the Future Innovator Prize followed AVM’s acquisition of LabCentral’s Gold Sponsorship in October 2019. Astellas and LabCentral are delighted to help scientists and early-stage enterprises in speeding up their unique treatment programs, modalities, or platforms, as part of their shared commitment to find and develop breakthrough science for the possible future benefit of patients around the globe.
President of AVM, Maruyama, expressed excitement over…
